Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06926478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Subconjunctival Humira for Boston Keratoprosthesis

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 1, 2026 to Oct 1, 2026
    • Site contact updated
    v3
  2. Start date: Aug 1, 2025 to Jun 1, 2026
    • Primary completion date: Aug 1, 2027 to Jun 1, 2027
    • Study completion date: Aug 1, 2028 to Jun 1, 2028
    • Site contact updated
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
Trial Details
NCT Number NCT06926478
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Related terms Pemphigoid, Benign Mucous Membrane, Stevens-Johnson Syndrome
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov